Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

28.53 -0.73 (-2.49%)

Streaming Delayed Price Updated: 2:18 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Demystifying Amphastar Pharma: Insights From 4 Analyst Reviews ↗

October 22, 2025

Via Benzinga

Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

3 Stocks Under $50 We’re Skeptical Of

October 07, 2025

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect

November 04, 2025

Via StockStory

1 of Wall Street’s Favorite Stock to Target This Week and 2 That Underwhelm

October 30, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

Topics Economy

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025

October 27, 2025

Via ACCESS Newswire

2 Reasons AMPH is Risky and 1 Stock to Buy Instead

October 27, 2025

Since April 2025, Amphastar Pharmaceuticals has been in a holding pattern, floating around $24.52. The stock also fell short of the S&P 500’s 22.9% gain during that period.

Via StockStory

Topics Economy Government Stocks

3 Value Stocks with Warning Signs

October 06, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Value Investor's Opportunity ↗

October 01, 2025

Amphastar Pharmaceuticals appears undervalued with a low P/E ratio, strong profitability, and solid financial health, fitting value investing criteria.

Via Chartmill

3 Low-Volatility Stocks with Open Questions

September 24, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

3 Small-Cap Stocks That Concern Us

September 19, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Presents a Compelling Value Investment Case ↗

September 09, 2025

Amphastar Pharmaceuticals (AMPH) is a value stock with strong profitability, a low P/E ratio, and solid financial health, trading below intrinsic value.

Via Chartmill

A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack

September 04, 2025

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Profitable Stocks We Steer Clear Of

August 29, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference

August 28, 2025

Via ACCESS Newswire

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Value Stock with Strong Fundamentals and Undervalued Potential ↗

August 18, 2025

Amphastar Pharmaceuticals (AMPH) offers strong value potential with low P/E ratios, high profitability, and stable finances, making it a solid pick for value investors seeking undervalued stocks.

Via Chartmill

Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know

August 12, 2025

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed...

Via StockStory

Topics Bonds Economy Lawsuit

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum ↗

August 12, 2025

FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch.

Via Benzinga

Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.

August 12, 2025

Via ACCESS Newswire

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

August 11, 2025

Via ACCESS Newswire

Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6%

August 08, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 4.4% year on year to $174.4 million. Its non-GAAP profit...

Via StockStory

Amphastar (AMPH) Q2 2025 Earnings Call Transcript ↗

August 07, 2025

Via The Motley Fool

Topics Earnings Supply Chain

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025

August 07, 2025

Via ACCESS Newswire

1 of Wall Street’s Favorite Stock to Target This Week and 2 We Find Risky

August 01, 2025

Via StockStory

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025

July 29, 2025

Via ACCESS Newswire

3 Low-Volatility Stocks with Questionable Fundamentals

July 24, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Topics Supply Chain

Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know

July 23, 2025

A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally.

Via StockStory

Topics Stocks World Trade

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today